相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness
Julius Gelzinsky et al.
HYPERTENSION RESEARCH (2020)
Association between advanced glycation end products, their soluble receptor, and mortality in the general population: Results from the CARLA study
Helen Ebert et al.
EXPERIMENTAL GERONTOLOGY (2020)
Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?
Kailash Prasad
MOLECULAR AND CELLULAR BIOCHEMISTRY (2019)
High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality
Helena Grauen Larsen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
sRAGE and early signs of cardiac target organ damage in mild hypertensives
Andrea Maria Maresca et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM
Edwin R. Miranda et al.
NUTRIENTS (2019)
Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes
Jenny M. Waden et al.
DIABETOLOGIA (2019)
Increased levels of soluble Receptor for Advanced Glycation End-products (RAGE) are associated with a higher risk of mortality in frail older adults
Lee Butcher et al.
AGE AND AGEING (2019)
Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE
Jisu Jeong et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension
Bogna Gryszczynska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?
Chinedum Eleazu et al.
FRONTIERS IN PHYSIOLOGY (2019)
1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease
Antonino Di Pino et al.
CELLS (2019)
Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes comorbidity and modulated by anti-tuberculosis treatment and metformin therapy
Nathella Pavan Kumar et al.
BMC INFECTIOUS DISEASES (2019)
Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus
Sinan Subhi Farhan et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2019)
Targeting RAGE Signaling in Inflammatory Disease
Barry I. Hudson et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Fasting blood soluble RAGE may be causally implicated in impaired glucose metabolism in Chinese patients with primary hypertension
Yuge Wang et al.
GENE (2018)
Protein Biomarkers of Cardiovascular Disease and Mortality in the Community
Jennifer E. Ho et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE
Foo Nian Wong et al.
PEERJ (2018)
Temporal reliability of serum soluble and endogenous secretory receptors for advanced glycation end-products (sRAGE and esRAGE) in healthy women
Fen Wu et al.
CANCER CAUSES & CONTROL (2018)
Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome
Simina-Ramona Selejan et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2018)
Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health
E. R. Miranda et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2018)
RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr-/- mice
Mitchell Bijnen et al.
SCIENTIFIC REPORTS (2018)
Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients
Elena Dozio et al.
MEDIATORS OF INFLAMMATION (2018)
The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients
Kuang-Hsing Chiang et al.
BMC ENDOCRINE DISORDERS (2018)
Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study
Colin Pearce et al.
INTERNATIONAL JOURNAL OF ANGIOLOGY (2018)
Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women
Elena Dozio et al.
EUROPEAN JOURNAL OF NUTRITION (2017)
Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients
Eul Sik Jung et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children
Reiko Saito et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2017)
Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation
Elena Dozio et al.
MEDIATORS OF INFLAMMATION (2017)
Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults
Tina E. Brinkley et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?
Kailash Prasad et al.
INTERNATIONAL JOURNAL OF ANGIOLOGY (2017)
Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes
Edwin R. Miranda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
Ani Manichaikul et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2017)
Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes
S. Goya Wannamethee et al.
ATHEROSCLEROSIS (2017)
The Relationship of Serum Soluble Receptor for Advanced Glycation End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic Nephropathy in Persons With Type 1 Diabetes
Ronald Klein et al.
DIABETES CARE (2017)
Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort
Stephanie J. Loomis et al.
CLINICAL CHEMISTRY (2017)
A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes
K. M. Salonen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase
Ivana Koborova et al.
CROATIAN MEDICAL JOURNAL (2017)
Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect
Mohamed Haddad et al.
DISEASE MARKERS (2016)
Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study
Radana Gurecka et al.
GLYCOCONJUGATE JOURNAL (2016)
Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes
Antonino Di Pino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Serum Levels of sRAGE Are Associated with Body Measurements, but Not Glycemic Parameters in Patients with Prediabetes
Metin Guclu et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2016)
Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks
Mohamed Rowisha et al.
PEDIATRIC RESEARCH (2016)
The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation
Terase F. Lancefield et al.
PLOS ONE (2016)
Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients
Byoung Ho Choi et al.
PLOS ONE (2016)
sVCAM-1 concentration and carotid IMT values in patients with acute myocardial infarction - Atherosclerotic markers of the presence, progress and prognosis
Anna Lisowska et al.
ADVANCES IN MEDICAL SCIENCES (2015)
Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)
Barry I. Hudson et al.
ATHEROSCLEROSIS (2015)
Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study
Martin Heier et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Huan Zheng et al.
CURRENT VASCULAR PHARMACOLOGY (2015)
Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects
Imke Hagen et al.
CYTOKINE (2015)
Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes
Merlin C. Thomas et al.
DIABETES CARE (2015)
Decrease in Circulating Concentrations of Soluble Receptors for Advanced Glycation End Products at the Time of Seroconversion to Autoantibody Positivity in Children With Prediabetes
Kirsi M. Salonen et al.
DIABETES CARE (2015)
Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients
Minglian Huang et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease
S. F. Bakker et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2015)
Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease
Ann Marie Schmidt
VASCULAR PHARMACOLOGY (2015)
Relationship of Soluble RAGE with Insulin Resistance and Beta Cell Function during Development of Type 2 Diabetes Mellitus
Subrata Kumar Biswas et al.
JOURNAL OF DIABETES RESEARCH (2015)
Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study
Casey M. Rebholz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients
Naohito Isoyama et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled trial (PioRAGE)
Hidenori Koyama et al.
ATHEROSCLEROSIS (2014)
Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)
Julie K. Bower et al.
CLINICAL BIOCHEMISTRY (2014)
Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects
Katarina Sebekova et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2014)
Role of AGEs-RAGE System in Cardiovascular Disease
Kei Fukami et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Circulating Concentrations of Soluble Receptor for AGE Are Associated With Age and AGER Gene Polymorphisms in Children With Newly Diagnosed Type 1 Diabetes
Kirsi M. Salonen et al.
DIABETES CARE (2014)
Two Soluble Isoforms of Receptors for Advanced Glycation End Products (RAGE) in Carotid Atherosclerosis: The Difference of Soluble and Endogenous Secretory RAGE
Saori Moriya et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2014)
Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults
Kathleen E. Davis et al.
NUTRITION RESEARCH (2014)
Soluble Form of Receptor for Advanced Glycation End Products Is Associated with Obesity and Metabolic Syndrome in Adolescents
Chih-Tsueng He et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2014)
Fructosamine 3-Kinase and Glyoxalase I Polymorphisms and Their Association With Soluble RAGE and Adhesion Molecules in Diabetes
J. Skrha et al.
PHYSIOLOGICAL RESEARCH (2014)
Functional Role of Soluble Receptor for Advanced Glycation End Products in Stroke
Sung-Chun Tang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients
Francesco Piarulli et al.
ATHEROSCLEROSIS (2013)
Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes
Keiko Fujisawa et al.
ATHEROSCLEROSIS (2013)
sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death
Elizabeth Selvin et al.
DIABETES (2013)
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
Koji Sakata et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Effect of insulin on the soluble receptor for advanced glycation end products (RAGE)
J. K. Y. Lam et al.
DIABETIC MEDICINE (2013)
Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD
Piera Boschetto et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis
Chang Hoon Ha et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013)
Protective mechanisms against oxidative stress and angiopathy in young patients with diabetes type 1 (DM1)
Nikolitsa Koutroumani et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2013)
Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels
Hyung Soo Kim et al.
NEPHROLOGY (2013)
Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension
K. Dimitriadis et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2013)
Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis
Helena Brodska et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2013)
Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients
Tarek M. K. Motawi et al.
BMC ENDOCRINE DISORDERS (2013)
Could Receptors for Advanced Glycation End Products Be Considered Cardiovascular Risk Markers in Obese Children?
Tommaso de Giorgis et al.
ANTIOXIDANTS & REDOX SIGNALING (2012)
Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis
Jwa-Kyung Kim et al.
ATHEROSCLEROSIS (2012)
Association between sRAGE, esRAGE levels and vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography
Sae Jeong Yang et al.
ATHEROSCLEROSIS (2012)
Soluble RAGE and malondialdehyde in type I diabetes patients without chronic complications during the course of the disease
Janice S. Reis et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Serum Levels of Receptors for Advanced Glycation End Products in Normal-Weight and Obese Children Born Small and Large for Gestational Age
Valentina Chiavaroli et al.
DIABETES CARE (2012)
Relationship of Soluble RAGE and RAGE Ligands HMGB1 and EN-RAGE to Endothelial Dysfunction in Type 1 and Type 2 Diabetes Mellitus
J. Skrha et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2012)
Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy
Peipei Kang et al.
GENE (2012)
Effects of Exercise on sRAGE Levels and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Kyung Mook Choi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Endogenous Secretory RAGE in Obese Women: Association with Platelet Activation and Oxidative Stress
Natale Vazzana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)
D. Leonardis et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2012)
Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score
Sergio Raposeiras-Roubin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
What Is the Significance of Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products in Liver Steatosis in Obese Prepubertal Children?
Ebe D'Adamo et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Elevated Serum Levels of Advanced Glycation End Products and their Monocyte Receptors in Patients with Type 2 Diabetes
Xu-dong Su et al.
ARCHIVES OF MEDICAL RESEARCH (2011)
Soluble Receptor of Advanced Glycated Endproducts Is Associated With Plaque Vulnerability in Patients With Acute Myocardial Infarction
Hun-Jun Park et al.
CIRCULATION JOURNAL (2011)
Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes
Xystus H. L. Tam et al.
CLINICAL SCIENCE (2011)
Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes An Analysis From the CARDS Trial
Helen M. Colhoun et al.
DIABETES (2011)
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes
M. C. Thomas et al.
DIABETOLOGIA (2011)
Arterial Calcification Is Driven by RAGE in Enpp1-/- Mice
Denise L. Cecil et al.
JOURNAL OF VASCULAR RESEARCH (2011)
Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes
H. L. Tam et al.
ATHEROSCLEROSIS (2010)
Soluble receptor for advanced glycation end products (sRAGE) in plasma and synovial fluid is inversely associated with disease severity of knee osteoarthritis
Maneerat Chayanupatkul et al.
CLINICAL BIOCHEMISTRY (2010)
Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention
Erick D. McNair et al.
CLINICAL CARDIOLOGY (2010)
Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients
Ayumu Nakashima et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Niccolo Lanati et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes A 12-Year Follow-Up Study
Johanna W. M. Nin et al.
DIABETES (2010)
Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage
Yu Jiang-Yi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Homodimerization Is Essential for the Receptor for Advanced Glycation End Products (RAGE)-mediated Signal Transduction
Hongliang Zong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Association of the RAGE G82S polymorphism with Alzheimer's disease
Jonny Daborg et al.
JOURNAL OF NEURAL TRANSMISSION (2010)
Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease
Giuseppina Basta et al.
KIDNEY INTERNATIONAL (2010)
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients
Ozen Oz Gul et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Kai Wang et al.
NUCLEIC ACIDS RESEARCH (2010)
Advanced Glycation End Products and Their Circulating Receptors and Level of Kidney Function in Older Community-Dwelling Women
Richard D. Semba et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes
Lin Lu et al.
ATHEROSCLEROSIS (2009)
Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes
Naoto Katakami et al.
ATHEROSCLEROSIS (2009)
Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients
Wen Hui Peng et al.
CLINICAL BIOCHEMISTRY (2009)
Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
Jason B. Lindsey et al.
DIABETES & VASCULAR DISEASE RESEARCH (2009)
Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis Observations from the Dallas Heart Study
Jason B. Lindsey et al.
DIABETES CARE (2009)
Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study
J. W. M. Nin et al.
DIABETOLOGIA (2009)
Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications
A. Bierhaus et al.
DIABETOLOGIA (2009)
Association of Polymorphism in the Receptor for Advanced Glycation End Products (RAGE) Gene with Circulating RAGE Levels
Katrien H. J. Gaens et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Association Between Serum Levels of the Soluble Receptor (sRAGE) for Advanced Glycation Endproducts (AGEs) and their Receptor (RAGE) in Peripheral Blood Mononuclear Cells of Children with Type 1 Diabetes Mellitus
Athina Dettoraki et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2009)
RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation
Louis J. Sparvero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population
Giuseppe Danilo Norata et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases
Helene Maillard-Lefebvre et al.
RHEUMATOLOGY (2009)
Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients
Erick D. McNair et al.
INTERNATIONAL JOURNAL OF ANGIOLOGY (2009)
Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation
Ellena Linden et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Severity of diabetic microvascular complications is associated with a low soluble RAGE level
N. Grossin et al.
DIABETES & METABOLISM (2008)
Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients
Naoto Katakami et al.
DIABETES & VASCULAR DISEASE RESEARCH (2008)
Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function
Tomohito Gohda et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes
Kazuo Nakamura et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2008)
A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)
Angela Raucci et al.
FASEB JOURNAL (2008)
Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases
Ling Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The role of advanced glycation end products in progression and complications of diabetes
Su-Yen Goh et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes
Kazuo Nakamura et al.
MICROVASCULAR RESEARCH (2008)
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications
Shi Fang Yan et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGES in both diabetic and non-diabetic subjects
K. Nakamura et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes
K. C. B. Tan et al.
DIABETOLOGIA (2007)
Soluble RAGE in type 2 diabetes: Association with oxidative stress
Eleonora Devangelio et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease
Kazuo Nakamura et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
Per M. Humpert et al.
CARDIOVASCULAR DIABETOLOGY (2007)
Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans
Yangsoo Jang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes
Junnosuke Miura et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Pregnancy-associated plasma protein A and soluble receptor for advanced glycation end products after kidney transplantation
Marta Kalousova et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2007)
Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via ß2 integrin Mac-1
Rille Pullerits et al.
ARTHRITIS AND RHEUMATISM (2006)
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
K. C. B. Tan et al.
DIABETOLOGIA (2006)
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects
Sho-ichi Yamagishi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Development of an ELISA for esRAGE and its application to type 1 diabetic patients
Shigeru Sakurai et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target
Diego Geroldi et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes
PM Humpert et al.
DIABETES CARE (2006)
Soluble receptor for advanced glycation end products in patients with decreased renal function
M Kalousová et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis
H Koyama et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs
CM Cheng et al.
MODERN PATHOLOGY (2005)
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension
D Geroldi et al.
JOURNAL OF HYPERTENSION (2005)
Articular chondrocytes express the receptor for advanced glycation end products - Potential role in osteoarthritis
RF Loeser et al.
ARTHRITIS AND RHEUMATISM (2005)
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men
C Falcone et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes
M Challier et al.
CLINICAL CHEMISTRY (2005)
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products
YL Chen et al.
JOURNAL OF IMMUNOLOGY (2004)
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques - Role of glycemic control
F Cipollone et al.
CIRCULATION (2003)
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes
R Candido et al.
CIRCULATION RESEARCH (2003)
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
TM Wendt et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Central role of RAGE-dependent neointimal expansion in arterial restenosis
T Sakaguchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response
MA Hofmann et al.
GENES AND IMMUNITY (2002)
分享论文
